Cardiome enters into distribution deal for Brinavess, shares +4.9%

|About: Cardiome Pharma Corporation (CRME)|By:, SA News Editor

Cardiome Pharma (CRME +4.9%) says its Correvio subsidiary signed a distribution deal for its atrial fibrillation treatment Brinavess (vernakalant IV) in the Swedish market; financial details were not been disclosed.

Coupled with recent data that demonstrated conversion to normal sinus rhythm in ~70% of patients treated with Brinavess who were experiencing atrial fibrillation for less than 48 hours, CRME expects Sweden will be a key market for the treatment's growth.